Results 1 to 10 of about 34,101 (170)
PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis [PDF]
European Urology Open ScienceBackground and objective: Olaparib is one of the earliest approved treatment options for metastatic castration-resistant prostate cancer (mCRPC). This systematic review and network meta-analysis aimed to determine the optimal olaparib strategy for ...
Yixian Li +6 more
doaj +2 more sources
Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells [PDF]
PharmaceuticalsBackground: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase ...
Szymon W. Kmiecik +5 more
doaj +2 more sources
British Journal of Clinical Pharmacology, 2015 Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)‐associated, platinum‐sensitive ovarian cancer. Olaparib inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway ...
S C, Goulooze, A F, Cohen, R, Rissmann
+6 more sources
Reactions Weekly, 2021 Olaparib is an oral anticancer drug that inhibits the poly adenosine diphosphate-ribose polymerase protein (PARP). It is approved for use in advanced ovarian, breast, pancreatic, and prostate cancers. For this review, we comprehensively searched the PubMed database and Google for randomized trials and meta-analyses using the ...
Vibhor Sharma, Aparna Sharma
+5 more sources
Frontiers in Endocrinology, 2023 BackgroundStudies using novel antiandrogens (NAA) in patients with metastatic castration-resistant prostate cancer (mCRPC) have shown overall survival benefit.
Xiangyu Chen +7 more
doaj +1 more source
MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress
Translational Oncology, 2021 Poly (ADP-ribose) polymerase (PARP) inhibitor olaparib selectively kills cancer cells with BRCA-deficiency and is approved for BRCA-mutated breast, ovarian and pancreatic cancers by FDA.
Jinwen Shi +6 more
doaj +1 more source
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Case Reports in Oncology, 2023 Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor.
Mana Sekine +3 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that
Xiuzhi Zhu +8 more
doaj +1 more source
Successful olaparib desensitization using a novel one-day protocol
Allergy, Asthma & Clinical Immunology, 2020 Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE ...
Rongbo Zhu +2 more
doaj +1 more source
Cells, 2023 The PARP inhibitor (PARPi) olaparib is currently the drug of choice for serous ovarian cancer (OC), especially in patients with homologous recombination (HR) repair deficiency associated with deleterious BRCA1/2 mutations.
Łukasz Biegała +3 more
doaj +1 more source